New Year Debut Of Another Biosimilar Humira In India
AbbVie may have managed to push back direct biosimilar competition to Humira (adalimumab) in the US by a few years, but 2018 has begun with the launch of yet another biosimilar of the blockbuster biologic in India. Hetero, the latest entrant, expects to maintain pricing parity with its peers on the domestic market.
You may also be interested in...
Boehringer Ingelheim has received its first EU biosimilar approval: Cyltezo, a version of AbbVie’s blockbuster drug Humira. The product will not be launched until after expiry of the adalimumab SPC in October 2018.
Agreement with AbbVie allows Amgen to launch its Humira biosimilar in Europe in 2018 and in the US in 2023; it may be akin to generic settlements but it is uncertain if other sponsors will get similar deals.
Hetero’s biosimilar version of AbbVie's Humira (adalimumab) appears on course to a debut in India and is set to follow peers like Zydus Cadila and Torrent, signaling the build-up of more competition for the blockbuster biologic across markets.